<DOC>
	<DOCNO>NCT02336594</DOCNO>
	<brief_summary>This Phase 1 , randomize , open-label , 4-way crossover pharmacokinetic ( PK ) pharmacodynamic ( PD ) study healthy adult male subject design assess relative bioavailability RDEA3170 2.5 mg tablet administer 10 mg dose ( 2.5 mg × 4 tablet ) single RDEA3170 10 mg tablet . This study also assess effect low-fat high-fat meal PK PD RDEA3170 10 mg tablet .</brief_summary>
	<brief_title>RDEA3170 Bioavailability Study</brief_title>
	<detailed_description />
	<criteria>Subject able understand study procedures risk involve willing provide write informed consent first studyrelated activity Subject body weight ≥ 50 kg ( 110 lb . ) body mass index ≥ 18 ≤ 40 kg/m2 Subject Screening serum urate level ≤ 7 mg/dL Subject free clinically significant disease medical condition , per Investigator 's judgment Subject history suspicion kidney stone Subject undergone major surgery within 3 month prior Screening Subject donate blood experienced significant blood loss ( &gt; 450 mL ) within 12 week prior Day 1 give plasma donation within 4 week prior Day 1 Subject inadequate venous access unsuitable vein repeat venipuncture Subject Screening serum creatinine value upper limit normal Screening Day 2 ( Admission ) Subject swallow multiple tablet Subject heavy caffeine drinker Subject unwilling comply dietary restriction study Subject unable unwilling comply study requirement situation condition , opinion Investigator , may interfere participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>